Patents by Inventor Ignacio Aliagas

Ignacio Aliagas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serine/threonine kinase inhibitors
    Patent number: 8815877
    Abstract: Compounds having the formula I wherein A, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 26, 2014
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, James Crawford, Wendy Lee, Simon Mathieu, Joachim Rudolph
  • Serine/threonine kinase inhibitors
    Patent number: 8637537
    Abstract: Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: January 28, 2014
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, James Crawford, Wendy Lee, Simon Mathieu, Joachim Rudolph
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20130225620
    Abstract: Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
    Type: Application
    Filed: August 24, 2012
    Publication date: August 29, 2013
    Applicant: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, James Crawford, Wendy Lee, Simon Mathieu, Joachim Rudolph
  • RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130018033
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: January 17, 2013
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Wendy Lee, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Guiling Zhao, Alexandre J. Buckmelter, Jonas Grina, Joshua D. Hansen, Ellen Laird, David Moreno, Li Ren, Steven Mark Wenglowsky
  • RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20120214811
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: August 23, 2012
    Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Simon Mathieu, Rebecca Pulk, Joachim Rudolph, Zhaoyang Wen
  • RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20120157453
    Abstract: Compounds of Formula II are useful for inhibition of Raf kinases. Methods of using compounds of Formula II and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: June 21, 2012
    Applicants: GENENTECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Steven Mark Wenglowsky
  • RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20120157439
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: June 21, 2012
    Applicants: GENENTECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Simon Mathieu, Rebecca Pulk, Joachim Rudolph, Zhaoyang Wen, Jonas Grina, Joshua D. Hansen, Ellen Laird, David Moreno, Li Ren, Steven Mark Wenglowsky
  • Pentacyclic kinase inhibitors
    Patent number: 7749994
    Abstract: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2, R3 and m are defined herein.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: July 6, 2010
    Assignees: Genentech, Inc., Hoffman-LaRoche, Inc. (US Only), F. Hoffman-LaRoche, AG (EX-US)
    Inventors: Thomas E. Rawson, Brian Safina, Jennafer Dotson, Aihe Zhou, Ignacio Aliagas-Martin, Jason Halladay, Jun Liang, Matthias Rueth, Bing-Yan Zhu, Frederick Brookfield, Michael Prime, Birong Zhang, Jun M. Li
  • TETRACYCLIC KINASE INHIBITORS
    Publication number: 20090131407
    Abstract: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula (I): I wherein X, Y, Z, R1, R2, R3, Ra, Rb, and n are as described herein.
    Type: Application
    Filed: December 14, 2006
    Publication date: May 21, 2009
    Inventors: Brian Safina, Thomas E. Rawson, Ignacio Aliagas-Martin, Bing-Yan Zhu
  • Serine Protease Inhibitors
    Publication number: 20070037813
    Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean Artis, Michael Dina, John Flygare, Richard Goldsmith, Regina Munroe, Alan Olivero, Richard Pastor, Thomas Rawson, Kirk Robarge, Daniel Sutherlin, Kenneth Weese, Aihe Zhou, Yan Zhu
  • Pentacyclic kinase inhibitors
    Publication number: 20070037791
    Abstract: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2, R3 and m are defined herein.
    Type: Application
    Filed: August 14, 2006
    Publication date: February 15, 2007
    Inventors: Thomas Rawson, Brian Safina, Jennafer Dotson, Aihe Zhou, Ignacio Aliagas-Martin, Jason Halladay, Jun Liang, Matthias Rueth, Bing-Yan Zhu
  • Serine protease inhibitors
    Publication number: 20050186198
    Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 25, 2005
    Inventors: Ignacio Aliagas-Martin, Dean Artis, Michael Dina, John Flygare, Richard Goldsmith, Regina Munroe, Alan Olivero, Richard Pastor, Thomas Rawson, Kirk Robarge, Daniel Sutherlin, Kenneth Weese, Aihe Zhou, Yan Zhu
  • Serine protease inhibitors
    Patent number: 6919369
    Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: July 19, 2005
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean R. Artis, Michael S. Dina, John A. Flygare, Richard A. Goldsmith, Regina A. Munroe, Alan G. Olivero, Richard Pastor, Thomas E. Rawson, Kirk D. Robarge, Daniel P. Sutherlin, Kenneth J. Weese, Aihe Zhou, Yan Zhu
  • Serine protease inhibitors
    Publication number: 20030212071
    Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Application
    Filed: August 19, 2002
    Publication date: November 13, 2003
    Applicant: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean R. Artis, Michael S. Dina, John A. Flygare, Richard A. Goldsmith, Regina A. Munroe, Alan G. Olivero, Richard Pastor, Thomas E. Rawson, Kirk D. Robarge, Daniel P. Sutherlin, Kenneth J. Weese, Aihe Zhou, Yan Zhu
  • Serine protease inhibitors
    Patent number: 6472393
    Abstract: Compounds having the structure shown below wherein A, B, N1, N2, X, Y, Q, R2, R5 and R6 are as defined herein are useful to inhibit serine protease enzymes, such as TF/factor VIIa factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: October 29, 2002
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean R. Artis, Michael S. Dina, John A. Flygare, Richard A. Goldsmith, Regina A. Munroe, Alan G. Olivero, Richard Pastor, Thomas E. Rawson, Kirk D. Robarge, Daniel P. Sutherlin, Kenneth J. Weese, Aihe Zhou, Yan Zhu